Extended Data Fig. 3: Baseline peptide immunogenicity.
From: Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial
a, IFNγ SFCs/million plated pre-treatment PBMCs for all neoantigen OLP pools. The dashed line depicts the threshold for response. Responsive peptides are labeled. n = 87 total peptides. b, IFNγ SFCs/million plated PBMCs at each timepoint for the responsive peptides identified in a. c, Flow cytometry detection of peptide responsiveness among pre-treatment CD8+ and CD4+ T cells. The dashed line depicts the threshold for response. Responsive peptides are labeled. n = 56 total peptides. d, Flow cytometry analysis at each timepoint for the responsive peptides identified in c.
